Nov 20, 2025, 12:00 AM
International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma
Background: Neoadjuvant immunotherapy for resectable stage III melanoma has demonstrated promising outcomes in recent trials, prompting a change in clinical practice in many countries. Although therap…
Holistic framework that advances understanding of melanoma pathogenesis and supports development of
Melanoma, a highly aggressive form of skin cancer, is shaped by a complex interplay of genetic, environmental, and lifestyle factors. This review provides a comprehensive synthesis of the macroscopic …
Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response
Background: Despite the success of combined cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) immune checkpoint blockade (cICB), the majority of patients…
Pembrolizumab-related toxicity in patients with advanced melanoma at Wellington and Waikato hospitals
Aim: Pembrolizumab has revolutionised the treatment of melanoma. Immune checkpoint inhibitors (ICI) are well tolerated in trials, but the real-world incidence of toxicities and their management are n…
SPOTS (Sun Protection Outreach Teaching by Students) programme demonstrated significant improvements in adolescents' knowledge, attitudes, and behaviors toward sun protection
Background: The Sun Protection Outreach Teaching by Students (SPOTS) program previously demonstrated benefits to adolescents and medical students in the Midwest. Six years later, there have been signi…
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) meta…
Adjuvant cemiplimab therapy led to longer disease-free survival than placebo among patients at high risk for recurrence of cutaneous SCC
Background: Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has …